Home Font Size: 1 2 3 Send to a Friend
Source: Morphotek, Inc.
Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.com
Judee Shuler Eisai Corporation of North America 201-746-2241 judee_shuler@eisai.com
Beth Meiklejohn Reverb—DBC 215-957-0300 x225 bmeiklejohn@dbcommunications.net
Morphotek Executive, Rodney Dausch, Named Small Company
CFO of the Year in the Greater Philadelphia Region
Award Recognizes Business Leadership and Financial Excellence
in the Small Company Category
Exton, PA – July 21, 2008 - Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, today announced that Mr. Rodney Dausch, Vice-President and CFO, received the Philadelphia Business Journal/Drexel LeBow College of Business’ Small Company CFO of the Year Award. According to the Journal, the award recognizes outstanding CFOs that strategically lead their company’s growth, profits, and marketing position in addition to maintain its reputation, ethics and accountability to its shareholders and community. Mr. Dausch was selected by an independent panel of judges and the award was presented at a luncheon event at the Sheraton Center City Hotel in Philadelphia on July 17, 2008.
The Philadelphia Business Journal and Drexel University’s LeBow College of Business strive to honor business executives in the Greater Philadelphia region who have demonstrated excellence in such areas as innovation, financial performance, and personal commitment to their businesses and communities.
Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology. The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.
About Eisai Corporation of North America
Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three areas of therapeutic focus: Integrative neuroscience including neurology and psychiatric medicines; gastrointestinal disorders; and integrative oncology including oncotherapy and supportive-care treatments. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 10,000 people worldwide and reported worldwide sales of 734.3 billion in FY2007 (year ended March 31, 2008). More than 50 percent of the group sales are derived from overseas business. For more information, please visit www.eisai.co.jp.